Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: BioCryst is a clinical-stage biopharmaceutical company focused on the discovery and development of enzyme inhibitors for the treatment of T-cell mediated disorders, oncology, influenza, hepatitis C, and cardiovascular disorders. The company has not yet commercialized any products and relies on equity financing, grants, and collaboration agreements to fund operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2005 | Nine Months Ended Sept 30, 2005 | Balance Sheet (Sept 30, 2005) |
|---|---|---|---|
| Revenues | $32 | $131 | N/A |
| Net Loss | $(7,645) | $(18,938) | N/A |
| Loss Per Share (Basic & Diluted) | $(0.29) | $(0.75) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $9,097 |
| Securities Held-to-Maturity | N/A | N/A | $25,786 |
| Total Current Assets | N/A | N/A | $31,479 |
| Total Current Liabilities | N/A | N/A | $3,447 |
| Accumulated Deficit | N/A | N/A | $(144,702) |
Liquidity: As of September 30, 2005, the company held approximately $34.9 million in cash, cash equivalents, and securities held-to-maturity. The company reported a monthly cash burn rate of approximately $2.1 million at the end of the third quarter of 2005, up from $1.5 million per month in 2004.
Material Changes vs. Prior Period
- Revenue Decline: Collaborative and other R&D revenues decreased 72.4% to $32,000 for the three months ended September 30, 2005, compared to $116,000 in the prior year period. This was primarily due to the nearing completion of a National Institutes of Health (NIH) SBIR grant for the hepatitis C program.
- Increased Expenses: Research and development (R&D) expenses increased 48.1% to $7.16 million for the quarter (from $4.84 million) and 24.2% to $17.6 million for the nine-month period. Increases were driven by contract research and clinical trial costs for lead candidates Fodosine (BCX-1777) and BCX-4208.
- Interest Income: Interest and other income increased 83.1% to $282,000 for the quarter, attributed to a more favorable interest rate environment.
- Capital Raise: In February 2005, the company completed a registered direct offering of 4.35 million shares at $5.50 per share, raising approximately $23.9 million gross ($22.7 million net).
Outlook, Risks, and Management Commentary
Outlook and Guidance: Management believes current funds will be sufficient to fund operations at least through 2006. However, the monthly burn rate is expected to increase in late 2005 and 2006 as the company advances clinical trials. The company plans to initiate a Phase IIb pivotal trial for Fodosine in T-cell leukemia early in 2006 and a psoriasis trial in the first half of 2006. Clinical trials for the hepatitis C candidate (BCX-4678) and neuraminidase inhibitor (peramivir) are expected to begin in mid-2006 and Q1 2006, respectively.
Key Risks:
- Capital Requirements: The company will require additional capital to complete development and commercialization. Failure to secure funding could force delays or elimination of programs.
- Clinical Trial Uncertainty: Positive results in early trials do not guarantee success in pivotal trials. Side effects or enrollment delays could halt development.
- Regulatory Approval: No products have received FDA approval. The company faces risks related to the complexity and cost of the regulatory process.
- Third-Party Dependence: The company relies heavily on third-party contract research organizations (CROs) and manufacturers for clinical trials and drug production.
- Accounting Changes: The company plans to adopt FASB Statement No. 123(R) effective January 1, 2006, which will require fair value recognition of stock-based compensation, likely increasing reported net losses.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34.9 million cash position against the projected $2.1 million monthly burn rate and the timeline for the next capital raise.
- Clinical Milestones: Monitor the initiation and results of the Phase IIb pivotal trial for Fodosine (BCX-1777) scheduled for early 2006.
- Revenue Sources: Assess the sustainability of revenue streams given the expiration of the NIH grant and the lack of product sales.
- Accounting Impact: Review the impact of the upcoming adoption of FASB 123(R) on future earnings per share and net loss reporting.
- Collaboration Status: Track progress in establishing new collaborative agreements to offset R&D costs, as the company currently has no established commercial partnerships with pharmaceutical companies.